Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

REFERENCES

• Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31:100 - 10; http://dx.doi.org/10.1093/carcin/bgp263; PMID: 19934210
   PubMed Web of Science ®Google Scholar
• Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr.. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287 - 9; http://dx.doi.org/10.1001/jama.1991.03460100089030; PMID: 1995976
   PubMed Web of Science ®Google Scholar
• Devesa SS, Blot WJ, Fraumeni JF Jr.. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049 - 53; http://dx.doi.org/10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; PMID: 9827707
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of prospective randomized trial (Radiation Therapy Oncology Group 85-01). JAMA 1999; 281:1623 - 7; http://dx.doi.org/10.1001/jama.281.17.1623; PMID: 10235156
   PubMed Web of Science ®Google Scholar
• Nemoto K. Current Status of Radiation Therapy-Evidence-based Medicine (EBM) of addition Therapy-Current Management of Patients with Esophageal Cancer. Nippon Igaku Hoshasen Gakkai Zasshi 2001; 62:132 - 7
   Google Scholar
• Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005; 31:453 - 60; http://dx.doi.org/10.1016/j.ejso.2005.02.026; PMID: 15922879
   PubMed Web of Science ®Google Scholar
• Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996; 14:156 - 63; PMID: 8558191
   PubMed Web of Science ®Google Scholar
• Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; CD001799; PMID: 16235286
   PubMedGoogle Scholar
• Ku GY, Ilson DH. Esophageal cancer: adjuvant therapy. Cancer J 2007; 13:162 - 7; http://dx.doi.org/10.1097/PPO.0b013e318074dbe7; PMID: 17620765
   PubMed Web of Science ®Google Scholar
• Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, et al. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. J Gastroenterol Hepatol 2009; 24:886 - 95; http://dx.doi.org/10.1111/j.1440-1746.2008.05732.x; PMID: 19655439
   PubMed Web of Science ®Google Scholar
• Czito BG, Willett CG. In Pursuit of Progress: Multimodality Strategies Will Form the Cornerstone of Cure for Esophageal Cancer. Gastrointest Cancer Res 2009 Mar–Apr; 3(2): 74–76.
   Google Scholar
• Lagarde SM, Vrouenraets BC, Stassen LP, van Lanschot JJ. Evidence-based surgical treatment of esophageal cancer: overview of high-quality studies. Ann Thorac Surg 2010; 89:1319 - 26; http://dx.doi.org/10.1016/j.athoracsur.2009.09.062; PMID: 20338377
   PubMed Web of Science ®Google Scholar
• Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142:3714 - 25; PMID: 2785562
   PubMed Web of Science ®Google Scholar
• Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992; 127:1446 - 50; http://dx.doi.org/10.1001/archsurg.1992.01420120080015; PMID: 1365692
   PubMed Web of Science ®Google Scholar
• Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus?. Oncology (Williston Park) 1994; 8:37 - 42, discussion 44-5, 50-2, 61; PMID: 7527642
   PubMedGoogle Scholar
• Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000; 6:4663 - 73; PMID: 11156218
   PubMed Web of Science ®Google Scholar
• Ekman S, Bergqvist M, Tell R, Bergström S, Lennartsson J. Hsp90 as a therapeutic target in patients with oesophageal carcinoma. Expert Opin Ther Targets 2010; 14:317 - 28; http://dx.doi.org/10.1517/14728221003621278; PMID: 20148718
   PubMed Web of Science ®Google Scholar
• Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 2002; 22:1737 - 54; PMID: 12168863
   PubMed Web of Science ®Google Scholar
• Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006; 6:1205 - 14; http://dx.doi.org/10.2174/156802606777812068; PMID: 16842157
   PubMed Web of Science ®Google Scholar
• Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300:1887 - 96; http://dx.doi.org/10.1001/jama.300.16.1887; PMID: 18940975
   PubMed Web of Science ®Google Scholar
• Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009; 1:12 - 25; http://dx.doi.org/10.4161/mabs.1.1.7347; PMID: 20046569
   PubMed Web of Science ®Google Scholar
• Dragovich T, Campen C. Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. J Oncol 2009:804108. Available in: http://www.ncbi.nlm.nih.gov/pubmed/19636422.
   Google Scholar
• Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71 - 81; http://dx.doi.org/10.1016/S1380-2933(97)00065-1; PMID: 9154469
   PubMedGoogle Scholar
• Crombet TC, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646 - 54; http://dx.doi.org/10.1200/JCO.2004.03.089; PMID: 15117987
   PubMed Web of Science ®Google Scholar
• Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5:375 - 9; http://dx.doi.org/10.4161/cbt.5.4.2522; PMID: 16575203
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649 - 55; http://dx.doi.org/10.1097/00000421-198212000-00014; PMID: 7165009
   PubMed Web of Science ®Google Scholar
• Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1948; 1:634 - 56; http://dx.doi.org/10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205 - 16; http://dx.doi.org/10.1093/jnci/92.3.205; PMID: 10655437
   PubMed Web of Science ®Google Scholar
• European organization for research and treatment of cancer.EORTC QLQ-C30. Available from: http://groups.eortc.be/qol/downloads/modules/specimen_20qlq_c30.pdf
   Google Scholar
• European organisation for research and treatment of cáncer. EORTC QLQ – OES18. Available from: http://groups.eortc.be/qol/downloads/modules/specimen_20qlq_oes18.pdf
   Google Scholar
• Essack M, Radovanovic A, Schaefer U, Schmeier S, Seshadri SV, Christoffels A, et al. DDEC: Dragon database of genes implicated in esophageal cancer. BMC Cancer 2009; 9:219; http://dx.doi.org/10.1186/1471-2407-9-219; PMID: 19580656
   PubMed Web of Science ®Google Scholar
• Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27:1130 - 6; http://dx.doi.org/10.1200/JCO.2008.19.8168; PMID: 19124802
   PubMed Web of Science ®Google Scholar
• Torres OJ, Peña L, Martínez LB, Padilla D, Rodríguez K. Impact of the GCP System in the Clinical Trials. Control Clin Trials 2003; 24:126S
   Google Scholar
• Ilson DH. New developments in the treatment of esophageal cancer. Clin Adv Hematol Oncol 2004; 2:97 - 104; PMID: 16163169
   PubMedGoogle Scholar
• Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12:6064 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-06-0910; PMID: 17062682
   PubMed Web of Science ®Google Scholar
• Jiménez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, et al. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 2008; 8:78; http://dx.doi.org/10.1186/1471-2407-8-78; PMID: 18366723
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang X, Sun W. Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol 2008; 9:375 - 87; http://dx.doi.org/10.1007/s11864-009-0097-1; PMID: 19396633
   PubMed Web of Science ®Google Scholar
• Wang W, Xue L, Liu H, Wang P, Xu P, Cai Y. Aberrant changes of Wnt2/beta-catenin signaling pathway induced by sodium nitroprusside in human esophageal squamous cell carcinoma cell lines. Cancer Invest 2010; 28:230 - 41; http://dx.doi.org/10.3109/07357900903095698; PMID: 19857041
   PubMed Web of Science ®Google Scholar
• Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep 2010; 23:1167 - 72; PMID: 20204306
   PubMed Web of Science ®Google Scholar
• Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res 2009; 3:153 - 61; PMID: 19742141
   PubMedGoogle Scholar
• Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667 - 73; http://dx.doi.org/10.1093/annonc/mdp069; PMID: 19549707
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines and Clinical Resources. Access 2011 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar